Henasen™ is recommended for treating venous circulation disorders (swollen legs, pain, restless legs)
and for treating symptoms due to acute hemorrhoidal attack.
Henasen™ is a venotonic (it increases venous tone) and a vasculoprotector (it increases resistance in
small blood vessels).

- Usual dosage : 2 tablets daily in two divided doses, midday and evening at meal times.
- Acute hemorrhoidal attack : 6 tablets per day for the first 4 days, then 4 tablets per day for 3 days

Acute hemorrhoidal attack:
If the hemorrhoid symptoms do not disappear within 15 days, you should ask your doctor for advice.
Venous circulation disorders:
The most effective way of taking this treatment is in combination with a healthy lifestyle.
Avoid exposure to the sun, heat, excessive standing and being overweight. Walking and wearing special
support stockings stimulate blood circulation.
If you are in any doubt, do not hesitate to ask your doctor or your pharmacist for advice.

No cases of interaction have been reported during treatment with Henasen 500 mg.

No teratogenic effects have been shown in several studies and no adverse effect have been reported in
human.
Breast-feeding:
In the absence of data on excretion in milk, treatment should be avoided during breast-feeding. Fertility:
Reproductive toxicity studies showed no effect on fertility in male and female rats (see section 5.3).

Diosmin and Hesperidin Tablet has no influence on the ability to drive or use machines.

Summary of the safety profile
Side effects reported with Henasen in clinical trials are of mild intensity. They consist mainly in gastro
intestinal events (diarrhoea, dyspepsia, nausea, vomiting).

Tabulated list of adverse reactions
The following adverse effects or events have been reported and are ranked using the following frequency:
very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to
<1/1,000); very rare (<1/10,000); not known (cannot be estimated form the available data).

* Post-marketing experience
To report any side effect(s):
• Saudi Arabia:
The National Pharmacovigilance and Drug Safety Centre (NPC)
Fax: +966-11-205-7662
Call NPC at +966-11-2038222,
Ext: 2317-2356-2353-2354-2334-2340.
Toll free phone: 8002490000
E-mail: npc.drug@sfda.gov.sa
Website: www.sfda.gov.sa/npc
• Other GCC States:
− Please contact the relevant competent authority.

No case of overdose has been reported until today.
If you do accidentally take too many tablets, seek medical attention straight away.

Pharmacotherapeutic group: Venotonic and vascular protector. ATC code: C05CA53.
Pharmacology
It is active upon the return vascular system in the following way:
 It reduces venous distensibility and stasis,
 In the microcirculation, it normalises capillary permeability and increases capillary resistance.
Clinical Pharmacology
Double blind controlled studies using methods by which the effects of the product on venous
haemodynamics could be demonstrated and quantifed have confirmed the above pharmacological
properties in man.
 Dose-effect relationship: a statistically significant dose-effect relationship was established with respect
to venous plethysmographic parameters: capacitance, distensibility and rate of emptying. The optimum
dose-effect ratio was obtained with 2 tablets.
 Venous tonic activity: Henasen 500 mg increases venous tone: venous occlusion plethysmography
with a mercury stress gauge demonstrated a decrease in the rate of emptying.
 Microcirculatory activity: double-blind controlled studies showed a statistically significant difference
between placebo and the drug. In patients presenting with signs of capillary fragility, Henasen 500 mg
increases capillary resistance, as measured by angiosterometry.
Clinical trials
Double-blind placebo-controlled trials have demonstrated the activity of the drug in phlebology, in the
treatment of chronic venous insufficiency of the lower limbs (both functional and organic).

In man, following oral administration of the substance containing 14C Diosmin:
- Excretion is mainly faecal, a mean of 14% of the dose administered is excreted in the urine.
- The elimination half-life is 11 hours.
- The drug is extensively metabolised as evidenced by the presence of various phenol acids in the urine.

In animals, experimental studies did not show any teratogenic effect.

 Microcrystalline Cellulose
 Sodium Starch Glycolate
 Sodium Lauryl Sulphate
 Gelatin
 Glycerol
 Talc
 Magnesium Stearate
 Opadry 02N230002 Orange
 Purified Water

Not applicable

Do not store above 30°C

Film Coated Tablets, 30‘s Alu - PVC/PVDC Blister

No special requirements.